Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, 6-Week, Double-blind, Placebo- Controlled Trial of Solriamfetol in Adolescents Aged 12 to <18 Years With Attention Deficit Hyperactivity Disorder (ADHD)

NCT07717892 is registered in ClinicalTrials.gov with Axsome Therapeutics, Inc. as lead sponsor.

NCT NCT07717892
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07717892 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, 6-Week, Double-blind, Placebo- Controlled Trial of Solriamfetol in Adolescents Aged 12 to <18 Years With Attention Deficit Hyperactivity Disorder (ADHD)
Lead sponsor
Axsome Therapeutics, Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
June 25, 2026
Completion date
June 30, 2028
Enrollment
468 (estimated)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

adhd